Ausra

Ausra is a biotechnology company focused on advancing the field of RNA therapeutics through the development of innovative delivery systems. The company's core technology centers on a proprietary lipid nanoparticle (LNP) platform designed to achieve extrahepatic delivery, enabling RNA medicines to reach tissues such as the lungs, heart, and muscle. By overcoming the historical limitation of LNP accumulation in the liver, Ausra aims to expand the reach of mRNA and siRNA therapies to a wider array of indications, including oncology and rare genetic diseases. Led by industry veterans with experience at Moderna and Alnylam, the company is positioned at the forefront of next-generation genomic medicine.